Acute Eosinophilic Pneumonia Following mRNA COVID-19 Vaccination: A Case Report

Piqueras, M. Barrio; Ezponda, Ana; Rodero, Carmen Felgueroso; Iriarte, None Cesar Urtasun; Frisco, I. Madeleine Di; Larrache, Javier; Bastarrika, Gorka; Ocaña, Ana Belén Alcaide

doi:10.1016/j.arbres.2021.11.004

Cited by 14 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the previous reports, the clinical symptoms of CVP usually improve immediately with systemic corticosteroid treatment as in the present cases. Two cases of CVP that showed spontaneous remission without any treatment have also been reported 6,7 . When the clinical symptoms and pulmonary infiltrates become worsened instead of medical treatment, other etiologies of lung injuries should be considered.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Three Cases of Coronavirus Disease 2019 Vaccine-associated Organizing Pneumonia

Ono,

Koyama,

Notohara

et al. 2023

Journal of Thoracic Imaging

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

“…The literature review revealed 27 cases of COVID-19 vaccine-associated pneumonia (CVP) 2–7 . CVP can occur either after the first, second, or subsequent vaccinations.…”

Section: Discussionmentioning

confidence: 99%

Three Cases of Coronavirus Disease 2019 Vaccine-associated Organizing Pneumonia

Ono,

Koyama,

Notohara

et al. 2023

Journal of Thoracic Imaging

View full text Add to dashboard Cite

“…These include cases of eosinophilic pneumonia, hypersensitivity, or other ILDs accountable to either BNT162b or ChAdOx1 nCov-19/AZD1222. 8 9 10 11 12 13 14 15 16 Regarding mRNA-1253 vaccine, Yoshimura et al 17 described a case of an 88-year-old female with dyspnea following 2 nd dose of mRNA-1253 whose postmortem lung specimen revealed proliferative stage of diffuse alveolar damage. To our knowledge, pneumonitis following Ad26.COV2.S vaccination has not been reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea: A Nationwide Multicenter Survey

et al. 2023

View full text Add to dashboard Cite

Background Recent reports have suggested that pneumonitis is a rare complication following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, its clinical features and outcomes are not well known. The aim of this study was to identify the clinical characteristics and outcomes of patients with vaccine-associated pneumonitis following vaccination against SARS-CoV-2. Methods In this nationwide multicenter survey study, questionnaires were distributed to pulmonary physicians in referral hospitals. They were asked to report cases of development or exacerbation of interstitial lung disease (ILD) associated with the coronavirus disease 2019 vaccine. Vaccine-associated pneumonitis was defined as new pulmonary infiltrates documented on chest computed tomography within 4 weeks of vaccination and exclusion of other possible etiologies. Results From the survey, 49 cases of vaccine-associated pneumonitis were identified between February 27 and October 30, 2021. After multidisciplinary discussion, 46 cases were analyzed. The median age was 66 years and 28 (61%) were male. The median interval between vaccination and respiratory symptoms was 5 days. There were 20 (43%), 17 (37%), and nine (19%) patients with newly identified pneumonitis, exacerbation of pre-diagnosed ILD, and undetermined pre-existing ILD, respectively. The administered vaccines were BNT162b2 and ChAdOx1 nCov-19/AZD1222 each in 21 patients followed by mRNA-1273 in three, and Ad26.COV2.S in one patient. Except for five patients with mild disease, 41 (89%) patients were treated with corticosteroid. Significant improvement was observed in 26 (57%) patients including four patients who did not receive treatment. However, ILD aggravated in 9 (20%) patients despite treatment. Mortality was observed in eight (17%) patients. Conclusion These results suggest pneumonitis as a potentially significant safety concern for vaccines against SARS-CoV-2. Clinical awareness and patient education are necessary for early recognition and prompt management. Additional research is warranted to identify the epidemiology and characterize the pathophysiology of vaccine-associated pneumonitis.

show abstract

“…The search strategy combined free text search, exploded medical subject headings (MESH/EMTREE) terms, and all synonyms of the following MESH terms to identify relevant published articles: “COVID-19”, “COVID-19 vaccines”, and “mRNA vaccines” in combination with “hypereosinophilic syndrome”. We identified a total of seven cases of hypereosinophilic conditions following the anti-SARS-CoV-2 vaccine and summarized the patients’ age, gender, clinical presentation, treatment, and outcome ( Table 1 ) [ 15 , 16 , 17 , 18 , 19 , 20 ].…”

Section: Discussionmentioning

confidence: 99%

“…There were five cases of pulmonary eosinophilia and two cases of HES [ 16 , 18 , 19 , 20 ]. One of the HES cases presented with eosinophilic myocarditis and periorbital and pitting edema [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Hypereosinophilic Syndrome Following the BNT162b2 (BioNTech/Pfizer) Vaccine Successfully Treated with Mepolizumab: A Case Report and Review of the Literature

Hoxha

Tomaselli

Minicucci

et al. 2023

JCM

View full text Add to dashboard Cite

Although an increasing number of real-life data confirm large-scale clinical trial findings on the efficacy and safety of SARS-CoV-2 vaccines, rare but severe adverse reactions have begun to emerge. Here, we report a full-blown hypereosinophilic syndrome (HES) following a BNT162b2 (BioNTech/Pfizer) vaccine. A 48-year-old man developed, 5 days after the first shot of the SARS-CoV-2 vaccine, erythematous and painful nodular lesions in the lower and upper limbs accompanied by widespread itching, acrocyanosis with gangrenous lesions at the tips of the first and fourth fingers of the right hand, as well as paresthesia in the right hand and foot. Investigations revealed isolated eosinophilia, occlusion of the right ulnar artery, and electromyography alteration compatible with multifocal sensory neuropathy, as well as minimal accentuation of the interstitial texture with some ground glass appearance. Despite treatment with prednisone in combination with warfarin, he developed thrombosis of the left ulnar artery. Therefore, therapy with an IL-5 inhibitor and acetylsalicylic was successfully added. Given the time interval between the onset of clinical manifestations and the vaccine shot, we believe that the mRNA vaccine triggered the eosinophilic response. This case evidences a possible link between HES and the SARS-CoV-2 vaccination. Mepolizumab, an IL-5 inhibitor, might be considered in steroid refractory cases.

show abstract

Acute Eosinophilic Pneumonia Following mRNA COVID-19 Vaccination: A Case Report

Cited by 14 publications

References 8 publications

Three Cases of Coronavirus Disease 2019 Vaccine-associated Organizing Pneumonia

Three Cases of Coronavirus Disease 2019 Vaccine-associated Organizing Pneumonia

COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea: A Nationwide Multicenter Survey

Hypereosinophilic Syndrome Following the BNT162b2 (BioNTech/Pfizer) Vaccine Successfully Treated with Mepolizumab: A Case Report and Review of the Literature

Contact Info

Product

Resources

About